Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $801.45B | 39x | 0.42 | $892.13 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.6% Upside | Upgrade to Pro+ | |
| J&J | NYSE | Healthcare | Pharmaceuticals | $572.36B | 27.2x | -7.06 | $237.30 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.5% Upside | Upgrade to Pro+ | |
| AbbVie | NYSE | Healthcare | Pharmaceuticals | $364.29B | 87.4x | -70.78 | $205.94 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.4% Upside | Upgrade to Pro+ | |
| Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $335.94B | 19.8x | 0.36 | $50.82 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
| AstraZeneca | NYSE | Healthcare | Pharmaceuticals | $312.32B | 30.6x | 0.68 | $199.71 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
| Novartis | OTC Markets | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $146.25 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $150.98 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.2% Downside | Upgrade to Pro+ | |
| Merck&Co | NYSE | Healthcare | Pharmaceuticals | $289.91B | 16.1x | 2.02 | $117.34 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
| UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | $285.18B | 23.6x | -1.61 | $312.25 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.1% Upside | Upgrade to Pro+ | |
| Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | $196B | 29.8x | 3.99 | $527.71 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.3% Upside | Upgrade to Pro+ | |
| Amgen | NASDAQ | Healthcare | Pharmaceuticals | $186.61B | 24.1x | 0.28 | $345.55 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0% Upside | Upgrade to Pro+ | |
| Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $176.58B | 11x | 6.03 | $39.90 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
| Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | $176.53B | 27.2x | -0.53 | $101.37 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.6% Upside | Upgrade to Pro+ | |
| Gilead | NASDAQ | Healthcare | Pharmaceuticals | $172.15B | 20.3x | 0.01 | $138.68 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
| Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $166.71B | 58.7x | 2.59 | $469.41 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ | |
| Pfizer | NYSE | Healthcare | Pharmaceuticals | $153.93B | 19.8x | -5.94 | $27.04 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
| Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | $140.56B | 39.5x | -8.59 | $198.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.7% Upside | Upgrade to Pro+ | |
| Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | $131.73B | 40.5x | 4.97 | $343.76 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.4% Upside | Upgrade to Pro+ | |
| Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $117.13B | 16.5x | 0.09 | $57.29 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.7% Upside | Upgrade to Pro+ | |
| GSK plc | OTC Markets | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $29.24 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $57.56 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.4% Downside | Upgrade to Pro+ | |
| Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $115.93B | 20.2x | 0.45 | $47.77 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
| Vertex | NASDAQ | Healthcare | Pharmaceuticals | $113.01B | 28.7x | 0.03 | $439.49 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
| Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $112.15B | 41.2x | -13.96 | $120.68 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | $111.29B | 24.2x | 2.59 | $86.70 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
| HCA | NYSE | Healthcare | Healthcare Providers & Services | $109.47B | 17.2x | 0.57 | $489.67 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11% Upside | Upgrade to Pro+ | |
| McKesson | NYSE | Healthcare | Pharmaceuticals | $105.66B | 24.8x | 0.41 | $862.03 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.9% Upside | Upgrade to Pro+ | |
| CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | $96.20B | 54x | -0.91 | $75.03 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
| Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | $95.65B | 33.2x | 0.59 | $64.33 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $89.67B | 32.8x | 2.67 | $27.21 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Regeneron Pharma | NASDAQ | Healthcare | Pharmaceuticals | $76.21B | 17.9x | 2.1 | $740.42 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
| Cigna | NYSE | Healthcare | Healthcare Providers & Services | $70.46B | 12x | 0.15 | $267.58 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
| Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | $67.83B | 12.3x | -6.64 | $308.76 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
| Hoya Corp | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $63.55B | 41.2x | 1.71 | $189.39 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
| Medline | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $62.62B | 30x | 0.02 | $47.99 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15% Upside | Upgrade to Pro+ | |
| Cencora Inc | NYSE | Healthcare | Healthcare Equipment & Supplies | $62.23B | 38.2x | 2.05 | $318.32 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
| Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | $60.15B | 19.5x | -3.18 | $27.60 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
| UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | $59.87B | 32.5x | 0.71 | $156.96 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
| Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | $56.15B | 80.2x | -1.73 | $34.52 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | $56.15B | 80.2x | -1.71 | $17.86 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
| argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $52.30B | 40x | 0.74 | $838.17 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
| Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | $50.79B | 20.1x | 1.89 | $120.72 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
| Siemens Healthineers ADR | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $50.59B | 21.9x | 2.86 | $22.62 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.3% Upside | Upgrade to Pro+ | |
| Cardinal Health | NYSE | Healthcare | Pharmaceuticals | $49.95B | 30.5x | 1.04 | $212.23 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
| Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $48.33B | 39.5x | -0.28 | $68.17 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.2% Upside | Upgrade to Pro+ | |
| CSL | OTC Markets | Healthcare | Pharmaceuticals | $47.79B | 34.9x | -0.68 | $25.43 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
| Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | $47.28B | -11.1x | 0.26 | $11.96 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
| IDEXX Labs | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $46.14B | 44.5x | 1.94 | $581.45 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.8% Upside | Upgrade to Pro+ | |
| Edwards Lifesciences | NYSE | Healthcare | Healthcare Equipment & Supplies | $44.92B | 42.7x | -0.58 | $77.97 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.2% Upside | Upgrade to Pro+ | |
| Becton Dickinson | NYSE | Healthcare | Healthcare Equipment & Supplies | $44.34B | 25.4x | 8.16 | $155.38 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ |